The US Food and Drug Administration (FDA) has expanded the indication for the MitraClip (Abbott) device to include patients with normal mitral valves who develop symptoms of heart failure and moderate ...

Abbott reported new study findings supporting the use of its Tendyne transcatheter mitral valve replacement (TMVR) system.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window LONDON -- ...

Surgical repair decreased MR more than MitraClip ®. In 12-month follow-up, 20% of MitraClip patients required surgery for mitral dysfunction versus 2% in surgical patients. Both groups had ...

Abbott (NYSE:ABT) has presented data for two of its devices to treat leaky heart valves at the Transcatheter Cardiovascular Therapeutics conference. In a statement released late Tuesday, the medical ...

A study from Abbott found that employing its cardiac valve repair implant during earlier phases of heart failure—when a patient’s leaky mitral valve is still considered to be functional—could lead to ...

Over the past few days, medtech's biggest names gathered in San Francisco for the Transcatheter Cardiovascular Therapies (TCT ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. A study meant to serve as a ...

April 2, 2025 | Mamas Mamas, Stefan Anker, and Volker Rudolph talk about their studies of MitraClip for functional MR in patients with heart failure. Receive the the latest news, research, and ...

The real-world Evoque and new TRILUMINATE findings provide an “extension” from the pivotal trials, Dharam Kumbhani says.